Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component

• US 20010001663A1
• Filed: 01/09/2001
• Published: 05/24/2001
• Est. Priority Date: 06/30/1994
• Status: Active Grant

• Current Assignee: Masahiko Mihara, Tadamitsu Kishimoto, Yoichiro Moriya, Yosiyuki Oshugi
• Original Assignee: Masahiko Mihara, Tadamitsu Kishimoto, Yoichiro Moriya, Yosiyuki Oshugi
• Inventors: Moriya, Yoichiro, Oshugi, Yosiyuki, Mihara, Masahiko, Kishimoto, Tadamitsu
• Granted Patent: US 8,017,121 B2
• Time in Patent Office: Days
• US Class Current: 424/141.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor.

The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

Claims

1. A pharmaceutical composition for treatment of chronic rheumatoid arthritis containing an interleukin-6 antagonist as an effective component.

2. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to

claim 1

, characterized in that said interleukin-6 antagonist suppresses abnormal growth of synovial cells occurring with chronic rheumatoid arthritis.

3. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to

claim 1

, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6.

4. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to

claim 2

, characterized in that said interleukin-6 is human interleukin-6.

5. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to

claim 1

, characterized in that said interleukin-6 antagonist is an antibody against interleukin-6 receptor.

6. A pharmaceutical composition for treatment of chronic rheumatoid arthritis according to

claim 2

, characterized in that said interleukin-6 receptor is human interleukin-6 receptor.

7. A synovial cell growth inhibitor containing an interleukin-6 antagonist as an effective component.

8. A synovial cell growth inhibitor according to

claim 7

, characterized in that said interleukin-6 antagonist is interleukin-6 antibody or interleukin-6 receptor antibody.